Acquisition by Janus Henderson Group Plc of 33500 shares of ARCA Biopharma at 3.4647 subject to Rule 16b-3

About 67% of ARCA Biopharma's investor base is looking to short. The analysis of current outlook of investing in ARCA Biopharma suggests that many traders are alarmed regarding ARCA Biopharma's prospects. ARCA Biopharma's investing sentiment overview a quick insight into current market opportunities from investing in ARCA Biopharma. Many technical investors use ARCA Biopharma stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  
Filed transaction by ARCA Biopharma 10 Percent Owner. Grant, award or other acquisition pursuant to Rule 16b-3(d)

Read at macroaxis.com
Acquisition of 33500 common stock at 3.4647 of ARCA Biopharma by Janus Henderson Group Plc on 10th of July 2024. This event was filed by ARCA Biopharma with SEC on 2024-07-10. Statement of changes in beneficial ownership - SEC Form 4

ARCA Biopharma Fundamental Analysis

We analyze ARCA Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ARCA Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ARCA Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Current Liabilities

Current Liabilities Comparative Analysis

ARCA Biopharma is currently under evaluation in current liabilities category among its peers. Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.

ARCA Biopharma Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with ARCA Biopharma stock to make a market-neutral strategy. Peer analysis of ARCA Biopharma could also be used in its relative valuation, which is a method of valuing ARCA Biopharma by comparing valuation metrics with similar companies.

Peers

ARCA Biopharma Related Equities

TPSTTempest Therapeutics   21.13   
0%
100.0%
RNXTRenovoRx   3.20   
0%
15.0%
INDPIndaptus Therapeutics   2.16   
0%
10.0%
SPROSpero Therapeutics   1.90   
0%
8.0%
FBRXForte Biosciences   1.86   
0%
8.0%
AVTEAerovate Therapeutics   1.56   
0%
7.0%
TILInstil Bio   0.78   
0%
3.0%
RZLTRezolute   0.68   
3.0%
0%
CTMXCytomX Therapeutics   1.83   
8.0%
0%
ANTXAN2 Therapeutics   2.86   
13.0%
0%
KTTAPasithea Therapeutics   3.01   
14.0%
0%
ADAGAdagene   5.37   
25.0%
0%
ACRVAcrivon Therapeutics,   8.64   
40.0%
0%
NXTCNextCure   10.52   
49.0%
0%
QNRXQuoin Pharmaceuticals   14.89   
70.0%
0%
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.

Other Consideration for investing in ARCA Stock

If you are still planning to invest in ARCA Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ARCA Biopharma's history and understand the potential risks before investing.
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Transaction History
View history of all your transactions and understand their impact on performance
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
FinTech Suite
Use AI to screen and filter profitable investment opportunities
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing